Common Genetic Variants in the PSCA Gene in Fluence Gene Expression
Total Page:16
File Type:pdf, Size:1020Kb
Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk Yi-Ping Fua, Indu Kohaara, Nathaniel Rothmanb, Julie Earlc, Jonine D. Figueroab, Yuanqing Yed, Núria Malatse, Wei Tanga, Luyang Liua, Montserrat Garcia-Closasb,f, Brian Muchmorea, Nilanjan Chatterjeeb, McAnthony Tarwaya, Manolis Kogevinasg,h,i,j, Patricia Porter-Gilla, Dalsu Barisb, Adam Mumya, Demetrius Albanesb, Mark P. Purdueb, Amy Hutchinsonk, Alfredo Carratol, Adonina Tardónh,m, Consol Serran, Reina García-Closaso, Josep Lloretap, Alison Johnsonq, Molly Schwennr, Margaret R. Karagass, Alan Schneds, W. Ryan Divert, Susan M. Gapsturt, Michael J. Thunt, Jarmo Virtamou, Stephen J. Chanocka, Joseph F. Fraumeni, Jr.b,1, Debra T. Silvermanb, Xifeng Wud, Francisco X. Realc,n, and Ludmila Prokunina-Olssona,1 aLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, and bDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; cEpithelial Carcinogenesis Group, Molecular Pathology Programme, Centro Nacional de Investigaciones Oncológicas, Madrid 28029, Spain; dDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030; eGenetic and Molecular Epidemiology Group, Spanish National Cancer Research Center, Madrid 28029, Spain; fDivision of Genetics and Epidemiology, Institute of Cancer Research, London SW7 3RP, United Kingdom; gCentre for Research in Environmental Epidemiology, Barcelona 08003, Spain; hMunicipal Institute of Medical Research, Barcelona 08003, Spain; iCentro de Investiación de Biomédica en Red Epidemiología y Salud Pública, Barcelona 08003, Spain; jNational School of Public Health, Athens 11521, Greece; kCore Genotyping Facility, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702; lRamón y Cajal University Hospital, Madrid 28034, Spain; mInstituto Universitario de Oncología, Universidad de Oviedo, Oviedo 33003, Spain; nDepartament de Ciències Experimentals i de la Salut, and pHospital del Mar-Institut Municipal d’Investigació Mèdica, Universitat Pompeu Fabra, Barcelona 08003, Spain; oUnidad de Investigación, Hospital Universitario de Canarias, La Laguna 38320, Spain; qVermont Cancer Registry, Burlington, VT 05401; rMaine Cancer Registry, Augusta, ME 04333; sDartmouth Medical School, Hanover, NH 03755; tEpidemiology Research Program, American Cancer Society, Atlanta, GA 30303; and uDepartment of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki 00271, Finland Contributed by Joseph F. Fraumeni, Jr., February 15, 2012 (sent for review January 11, 2012) Genome-wide association studies have identified a SNP, rs2294008, genetic architecture of bladder cancer by discovering a number of on 8q24.3 within the prostate stem cell antigen (PSCA)gene,asa new bladder cancer-associated loci (13–17). risk factor for bladder cancer. To fine-map this region, we imputed One of these variants to achieve genome-wide significance with 642 SNPs within 100 Kb of rs2294008 in addition to 33 markers bladder cancer was SNP rs2294008 (C/T) within the prostate stem PSCA genotyped in one of the reported genome-wide association study cell antigen ( ) gene on 8q24.3 (14, 15). PSCA is a glyco- sylphosphatidylinositol-anchored cell membrane glycoprotein ini- in 8,652 subjects. A multivariable logistic regression model adjusted fi fi for rs2294008 revealed a unique signal, rs2978974 (r2 =0.02,D′ = 0.19 tially identi ed as a prostate-speci c cell-surface antigen (18), but with rs2294008). In the combined analysis of 5,393 cases and 7,324 later found to be expressed in many human tissues. Humanized controls, we detected a per-allele odds ratio (OR) = 1.11 [95% confi- monoclonal anti-PSCA antibodies are currently under evaluation − in clinical trials for the treatment of pancreatic and prostate cancers dence interval (CI) = 1.06–1.17, P =5.8× 10 5] for rs2294008 and OR = – P × −3 (19, 20). Although many studies have supported the important role 1.07 (95% CI = 1.02 1.13, =9.7 10 ) for rs2978974. The effect was of PSCA in carcinogenesis, little is known about the function of stronger in carriers of both risk variants (OR = 1.24, 95% CI = 1.08– PSCA P × −3 fi in normal and tumor tissues. 1.41, =1.8 10 )andtherewasasigni cant multiplicative in- In this study, we aimed to comprehensively explore the genetic P teraction ( = 0.035) between these two SNPs, which requires repli- landscape of the PSCA region to map genetic variants contributing cation in future studies. The T risk allele of rs2294008 was associated to bladder cancer susceptibility, as well as to investigate the mo- with increased PSCA mRNA expression in two sets of bladder tumor lecular phenotype of these variants and their role in cancer biology. samples (n =36,P = 0.0007 and n =34,P = 0.0054) and in normal bladder samples (n =35,P = 0.0155), but rs2978974 was not associ- Results ated with PSCA expression. SNP rs2978974 is located 10 Kb upstream Fine-Mapping and Genetic Association of the PSCA Region. PSCA is of rs2294008, within an alternative untranslated first exon of PSCA. located in 8q24.3 locus, 12.5 Mb telomeric from the region asso- The non-risk allele G of rs2978974 showed strong interaction with ciated with multiple cancers (21). Based on the combined reference nuclear proteins from five cell lines tested, implying a regulatory panel of the 1000 Genomes Project and HapMap 3 CEU (Utah function. In conclusion, a joint effect of two PSCA SNPs, rs2294008 residents with Northern and Western European ancestry) data, we and rs2978974, suggests that both variants may be important for expanded the SNP coverage of the 200 Kb PSCA region (chr8: bladder cancer susceptibility, possibly through different mechanisms 143,658,933–143,858,933, University of California at Santa Cruz that influence the control of mRNA expression and interaction with (UCSC) genome build hg18), which covers eight genes: ARC, JRK, regulatory factors. PSCA, LY6K, C8orf55, SLURP1, LYPD2,andLYNX1. In addition rinary bladder cancer ranks as the ninth most common ma- Ulignancy worldwide (1) and the sixth in the United States, with Author contributions: Y.-P.F., I.K., N.R., J.E., J.D.F., S.J.C., J.F.F., D.T.S., X.W., F.X.R., and L.P.-O. designed research; Y.-P.F., I.K., J.E., Y.Y., N.M., W.T., L.L., B.M., M.T., M.K., P.P.-G., D.B., 73,510 new cases and 14,880 deaths expected in the United States A.M., D.A., M.P.P., A.H., A.C., A.T., C.S., R.G.-C., J.L., A.J., M.S., M.R.K., A.S., W.R.D., S.M.G., in 2012 (2). Because of a 70% 10-y survival rate and 50–70% re- M.J.T., J.V., X.W., F.X.R., and L.P.-O. performed research; J.D.F., M.G.-C., and N.C. contrib- currence rate (3), patients require life-long surveillance and treat- uted new reagents/analytic tools; Y.-P.F., I.K., J.E., J.D.F., Y.Y., W.T., M.G.-C., N.C., X.W., ment, making bladder cancer one of the most expensive cancers F.X.R., and L.P.-O. analyzed data; N.R., Y.Y., N.M., M.G.-C., M.K., D.B., D.A., M.P.P., A.H., A.C., A.T., C.S., R.G.-C., J.L., A.J., M.S., M.R.K., A.S., W.R.D., S.M.G., M.J.T., J.V., S.J.C., J.F.F., to live with and a major economic burden on the health care system D.T.S., X.W., and F.X.R. subject enrollment and data collection; and Y.-P.F., I.K., N.R., S.J.C., (4, 5). Cigarette smoking and occupational exposures to aromatic J.F.F., D.T.S., X.W., F.X.R., and L.P.-O. wrote the paper. amines are established risk factors for bladder cancer (6). The authors declare no conflict of interest. – Genetic factors are estimated to explain 7 31% of bladder cancer Freely available online through the PNAS open access option. susceptibility (7, 8). Traditional candidate gene association studies 1To whom correspondence may be addressed. E-mail: [email protected] or prokuninal@ focused on genes involved in detoxification of environmental car- mail.nih.gov. – cinogens and DNA repair pathways (9 12). Recently, genome-wide This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. association studies (GWAS) have advanced our knowledge of the 1073/pnas.1202189109/-/DCSupplemental. 4974–4979 | PNAS | March 27, 2012 | vol. 109 | no. 13 www.pnas.org/cgi/doi/10.1073/pnas.1202189109 Downloaded by guest on September 29, 2021 region, we adjusted for the effect of rs2294008 along with age, sex, study regions, and smoking habit, and found the strongest signal for an additional variant, already genotyped in the GWAS, rs2978974 − (OR = 1.11, 95% CI = 1.04–1.19, P = 1.80 × 10 3)(Fig.1B and Dataset S1). Among 446 markers examined in this study, 46 SNPs areinstrongLD(r2 > 0.8) with rs2294008, but rs2978974 is a unique variant that is in low LD with rs2294008 (D′ = 0.19, r2 = 0.02) and 2 not well tagged by other SNPs (r max = 0.19) (Fig. S1 and Dataset S1). Additionally, rs2294008 and rs2978974 were genotyped in three independent studies, New England Bladder Cancer Study from New Hampshire (NEBCS-NH, a component of NEBCS not used in stage 1 GWAS), and Texas Bladder Cancer Study discovery set and validation set (TXBCS1 and TXBCS2, respectively). In the combined analysis of all eight studies that included 5,393 cases and 7,324 controls, rs2294008 and rs2978974 were associated with bladder cancer with a per-allele OR = 1.11 (95% CI = 1.06–1.17, − P = 5.79 × 10 5) and OR = 1.07 (95% CI = 1.02–1.13, P = 9.66 × − 10 3), respectively (Table 1).